Quality of Life and Adherence to Therapy in Patients With Chronic Myeloid Leukemia Treated With Nilotinib as a Second-Line Therapy: A Multicenter Prospective Observational Study.

Introduction: The aim of this study was to evaluate quality of life (QOL) and adherence to the therapy in patients with chronic myeloid leukemia in chronic phase treated with nilotinib as second-line therapy.

Patients And Methods: A multicenter, prospective, observational trial with 6 time points was conducted; 177 patients were recruited in 23 centers in Poland who were treated with nilotinib as second-line therapy because of the ineffectiveness or intolerance of their previous therapy. QOL was evaluated with the standard European Organization for Research and Treatment of Cancer Core Quality of Life questionnaire.

[Candida infections in immunocompromised hosts].

Candida infections in the immunocompromised patients represent a major therapeutic challenge. In immunocompromised host candidiasis can range from asymptomatic oral thrush to life-threatening candidemia. Invasive Candida infections parallel increase in the immunocompromised patient population and are characterized by high mortality.